Jul 8, 2026 04:05PM
Jul 1, 2026 04:05PM
Jun 30, 2026 08:05AM
Jun 30, 2026 08:05AM
Jun 25, 2026 08:05AM
Jun 25, 2026 08:05AM
Jun 2, 2026 08:05AM Candel publishes phase 3 prostate cancer trial data in Lancet Oncology
Jun 2, 2026 08:05AM
Jun 1, 2026 04:05PM
May 15, 2026 04:05PM
May 15, 2026 04:05PM
May 14, 2026 08:05AM
May 13, 2026 08:05AM
May 4, 2026 08:05AM Candel Therapeutics schedules call on prostate cancer trial data
May 4, 2026 08:05AM
May 1, 2026 04:05PM
Apr 29, 2026 08:05AM
Apr 29, 2026 08:05AM
Apr 2, 2026 04:05PM
Mar 17, 2026 08:05AM
Mar 17, 2026 08:05AM Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoin
Mar 13, 2026 06:10AM
Mar 12, 2026 08:05AM
Mar 9, 2026 08:05AM
Mar 9, 2026 08:05AM
Mar 2, 2026 04:05PM
Feb 24, 2026 08:05AM
Feb 19, 2026 09:40PM Candel Therapeutics prices $100 million public offering at $5.45 per share
Feb 19, 2026 09:40PM
Feb 19, 2026 04:05PM
Feb 19, 2026 04:05PM
Feb 19, 2026 04:02PM
Feb 19, 2026 04:01PM
Feb 11, 2026 08:05AM
Feb 2, 2026 04:05PM Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 17, 2025 04:05PM
Nov 17, 2025 04:05PM
Nov 13, 2025 08:25AM
Nov 4, 2025 09:00AM
Nov 4, 2025 09:00AM
Nov 3, 2025 08:05AM
Oct 16, 2025 08:05AM Candel Therapeutics adds systems immunology expert to advisory board
Oct 16, 2025 08:05AM
Oct 14, 2025 08:12AM
Oct 14, 2025 08:10AM
Oct 14, 2025 08:10AM
Oct 14, 2025 08:07AM
Oct 14, 2025 08:05AM
Oct 7, 2025 06:47AM H.C. Wainwright Reiterates Buy Rating on Candel Therapeutics Inc. (CADL)
Oct 3, 2025 09:05AM

325,890 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All